Anthos boss John Glasspool becomes VarmX CEO

VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive.

Mr Glasspool joins from the position of CEO at Anthos Therapeutics, a clinical-stage biopharma developing therapies for high-risk cardiovascular patients, including FXI inhibitors, so is very familiar with the therapeutic space in which VarmX is developing its lead asset VMX-C001.

In total, Mr Glasspool has more than 30 years’ experience within the global biopharma industry, linking science and business. His expertise includes building and growing companies, fundraising and investing, licensing, partnering and commercialization.